东方海洋：产品高敏心肌肌钙蛋白I测定试剂盒取得注册证

Group 1 - The core point of the article is that Dongfang Ocean's subsidiary, Aiveke Biotechnology, has received regulatory approval for its high-sensitivity cardiac troponin I testing kit, which is a significant development for the company [1] - The product, named "High-Sensitivity Cardiac Troponin I (hs-cTnI) Testing Kit (Fluorescent Immunochromatography Method)," has been registered with the Shandong Provincial Drug Administration [1] - As of the report, Dongfang Ocean's market capitalization stands at 4.7 billion yuan [1] Group 2 - For the first half of 2025, Dongfang Ocean's revenue composition is as follows: 73.14% from the aquaculture processing industry, 10.19% from in vitro diagnostics, 9.97% from marine aquaculture, and 6.7% from other businesses such as leasing [1]